Although the study was terminated prematurely due to new guideline recommendations regarding the use of SGLT2 inhibitors, the CANA-HF study (2020) reported similar findings to ours in a 12-week study that canagliflozin did not improve the peak VO2 and VE/VCO2 slope (25). This evidence concerns the gene SLC5A2 and hydrops fetalis.